文献速递生殖医学

微小RNA在卵巢功能中的作用及生育力保护新型治疗策略的转化前景

The role of microRNAs in ovarian function and the transition toward novel therapeutic strategies in fertility preservation: from bench to future clinical application.
PubMed 文献 · Hum Reprod Update · 2020-01-01

本文综述微小RNA(miRNA)在卵巢中的生理作用及其作为生育力保护靶点的潜力。文章基于PubMed与Google Scholar截至2019年的英文文献系统检索,结合肿瘤学中miRNA疗法的进展,提出纳米载体递送miRNA以减少化疗所致卵泡损伤的辅助保护策略。

要点

  • miRNA调控卵泡生长、闭锁与类固醇生成,并参与DNA损伤修复反应。
  • 化疗可改变miRNA表达,使其成为肿瘤治疗中卵巢保护的潜在靶点。
  • 纳米载体递送miRNA有望成为未来非侵入性生育力保护工具。

核心结论

  • miRNA有望在未来发展为强大且非侵入性的生育力保护工具。
  • 肿瘤学中miRNA疗法的经验可启发肿瘤生育力领域的辅助保护策略。

研究设计与样本

  • 综述类:系统检索PubMed与Google Scholar截至2019年的英文文献。
  • 检索内容涵盖miRNA在卵巢中的作用及其在肿瘤诊断与靶向治疗中的应用。
  • 结合个人数据展示靶向性腺、减少化疗所致卵泡损伤的miRNA治疗策略。

主要发现

  • miRNA是卵泡发育的调控因子,参与卵泡生长、闭锁与类固醇生成的调节。
  • miRNA参与DNA损伤修复反应,并可在化疗期间被调控。
  • 纳米技术的进步为使用新一代miRNA纳米载体开发药物提供了机会。

临床怎么用

  • 可关注miRNA作为化疗期间卵巢损伤辅助保护靶点的转化潜力。
  • 未来药物开发可探索miRNA纳米载体向卵巢的递送。

局限性

  • 这些治疗仍存在免疫原性与毒性方面的障碍。
  • 将miRNA特异性递送至卵巢仍有改进空间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: New therapeutic approaches in oncology have converted cancer from a certain death sentence to a chronic disease. However, there are still challenges to be overcome regarding the off-target toxicity of many of these treatments. Oncological therapies can lead to future infertility in women. Given this negative impact on long-term quality of life, fertility preservation is highly recommended. While gamete and ovarian tissue cryopreservation are the usual methods offered, new pharmacological-based options aiming to reduce ovarian damage during oncological treatment are very attractive. In this vein, advances in the field of transcriptomics and epigenomics have brought small noncoding RNAs, called microRNAs (miRNAs), into the spotlight in oncology. MicroRNAs also play a key role in follicle development as regulators of follicular growth, atresia and steroidogenesis. They are also involved in DNA damage repair responses and they can themselves be modulated during chemotherapy. For these reasons, miRNAs may be an interesting target to develop new protective therapies during oncological treatment. This review summarizes the physiological role of miRNAs in reproduction. Considering recently developed strategies based on miRNA therapy in oncology, we highlight their potential interest as a target in fertility preservation and propose future strategies to make the transition from bench to clinic. OBJECTIVE AND RATIONALE: How can miRNA therapeutic approaches be used to develop new adjuvant protective therapies to reduce the ovarian damage caused by cytotoxic oncological treatments? SEARCH METHODS: A systematic search of English language literature using PubMed and Google Scholar databases was performed through to 2019 describing the role of miRNAs in the ovary and their use for diagnosis and targeted therapy in oncology. Personal data illustrate miRNA therapeutic strategies to target the gonads and reduce chemotherapy-induced follicular damage. OUTCOMES: This review outlines the importance of miRNAs as gene regulators and emphasizes the fact that insights in oncology can inspire new adjuvant strategies in the field of onco-fertility. Recent improvements in nanotechnology offer the opportunity for drug development using next-generation miRNA-nanocarriers. WIDER IMPLICATIONS: Although there are still some barriers regarding the immunogenicity and toxicity of these treatments and there is still room for improvement concerning the specific delivery of miRNAs into the ovaries, we believe that, in the future, miRNAs can be developed as powerful and non-invasive tools for fertility preservation.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Alexandri C, Daniel A, Bruylants G, et al. The role of microRNAs in ovarian function and the transition toward novel therapeutic strategies in fertility preservation: from bench to future clinical application. Hum Reprod Update. 2020. PMID: 32074269. doi:10.1093/humupd/dmz039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。